ROLE OF CRIZANLIZUMAB FOR SICKLE RED CELLS DISEASE Authors: Chaturvedi P* And Shah SR
ABSTRACT
Sickle cell disease (SCD) is an inherited monogenic disease characterized by distorted red
blood cells that causes vaso-occlusion and vasculopathy. These red cells can damage the
vessel wall and activate P-selectine which can cause the vessel wall stick to other blood
constitute and form cluster. These clusters in the blood stream can create the blockage and
obstruct the flow of blood and oxygen in the tissues. Crizanlizumab is a humanized
monoclonal antibody binds to P-selectine and blocks the interaction of endothelium and
blood constituents. It’s infusion into the vein reduce the adhesion of blood vessel and cells
and prevent from vaso-occlusion crises. In this present model bio-physical properties of
distorted red blood cells studied in sickle cell disease. In steady-state, at very low Reynolds
number (inertial effect neglected) lubrication theory has been implemented to study the effect
of deformation parameter and compliance of the red blood cells in the blood flow due to
adhesion. The governing equations have been solved for suitable boundary and matching
conditions. The results have been shown graphically and agree semi quantitatively with
experimental results. Sickle RBCs are highly viscous liquid filled membranes, In the
microcirculation after releasing the oxygen to tissue Hb-SS turn into more rigid red blood
cells, leads to decrease cell velocity as compared to the healthy red blood cell. Slip effect has
been discussed in the reference of adhesion for blockage in the blood stream in more viscous
region due to diseased state. Results also verify that plasma in the capillary on the average
moves slower than the cells. It is concluded that rheological and bio-mechanical properties of the sickle RBCs and sickle blood plays an essential role in better understanding of the
pathophysiology of the disease.
Keywords: Pathophysiology, Vaso-oclusive, Crizanlizumab, Sickle cell disease, Reynolds
number
Publication date: 01/03/2023 https://ijbpas.com/pdf/2023/March/MS_IJBPAS_2023_6946.pdfDownload PDFhttps://doi.org/10.31032/IJBPAS/2023/12.3.6946